Centessa Pharmaceuticals plc (NASDAQ:CNTA) Receives Consensus Recommendation of “Buy” from Brokerages

Centessa Pharmaceuticals plc (NASDAQ:CNTA) has earned an average recommendation of “Buy” from the seven brokerages that are currently covering the firm, MarketBeat Ratings reports. Seven research analysts have rated the stock with a buy rating. The average 1-year target price among analysts that have covered the stock in the last year is $25.83.

A number of equities analysts have recently commented on the stock. Guggenheim increased their price target on shares of Centessa Pharmaceuticals from $24.00 to $28.00 and gave the stock a “buy” rating in a report on Friday, November 15th. TD Cowen started coverage on Centessa Pharmaceuticals in a research report on Tuesday, January 7th. They set a “buy” rating on the stock.

Insider Buying and Selling at Centessa Pharmaceuticals

In related news, CEO Saurabh Saha sold 1,671 shares of the company’s stock in a transaction that occurred on Friday, November 22nd. The stock was sold at an average price of $18.24, for a total transaction of $30,479.04. Following the completion of the transaction, the chief executive officer now owns 575,661 shares in the company, valued at $10,500,056.64. This represents a 0.29 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CTO Tia L. Bush sold 17,813 shares of Centessa Pharmaceuticals stock in a transaction on Tuesday, December 17th. The shares were sold at an average price of $18.00, for a total transaction of $320,634.00. Following the completion of the sale, the chief technology officer now owns 147,615 shares in the company, valued at approximately $2,657,070. This trade represents a 10.77 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 349,226 shares of company stock worth $6,036,765. 11.59% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in CNTA. Jane Street Group LLC bought a new stake in Centessa Pharmaceuticals during the 3rd quarter valued at about $2,834,000. Wellington Management Group LLP purchased a new position in Centessa Pharmaceuticals during the third quarter valued at $1,609,000. Nantahala Capital Management LLC bought a new position in shares of Centessa Pharmaceuticals during the 2nd quarter valued at approximately $4,064,000. Ally Bridge Group NY LLC bought a new stake in shares of Centessa Pharmaceuticals during the 3rd quarter valued at $4,951,000. Finally, State Street Corp purchased a new stake in shares of Centessa Pharmaceuticals during the third quarter worth about $777,000. Hedge funds and other institutional investors own 82.01% of the company’s stock.

Centessa Pharmaceuticals Price Performance

Shares of NASDAQ:CNTA opened at $16.46 on Wednesday. Centessa Pharmaceuticals has a 12 month low of $7.38 and a 12 month high of $18.97. The company has a current ratio of 21.52, a quick ratio of 21.52 and a debt-to-equity ratio of 0.15. The stock has a market cap of $2.17 billion, a P/E ratio of -10.76 and a beta of 1.53. The company has a 50 day moving average of $16.83 and a 200 day moving average of $14.77.

Centessa Pharmaceuticals (NASDAQ:CNTA) last posted its earnings results on Tuesday, November 12th. The company reported ($0.37) EPS for the quarter, topping the consensus estimate of ($0.42) by $0.05. As a group, sell-side analysts forecast that Centessa Pharmaceuticals will post -1.6 EPS for the current fiscal year.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.